Detection of Tumor‐Associated Autoantibodies in the Sera of Pancreatic Cancer Patients Using Engineered MUC1 Glycopeptide Nanoparticle Probes
Angewandte Chemie International Edition · 09.09.2024 · 63 (37)
DOI: 10.1002/anie.202407131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 07.08.2024. Verfasst von Francisco Corzana und 20 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Química, Instituto de Investigación en Química (IQUR), Universidad de La Rioja, Logroño, 26006 Logroño, Spain. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Mucin-1, Glycopeptides, Autoantibodies. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE Marie Sklodowska-Curie Actions, Mizutani Foundation for Glycoscience, Fundación Científica Asociación Española Contra el Cáncer.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Pancreatic cancer is one of the deadliest cancers worldwide, mainly due to late diagnosis. Therefore, there is an urgent need for novel diagnostic approaches to identify the disease as early as possible. We have developed a diagnostic assay for pancreatic cancer based on the detection of naturally occurring tumor associated autoantibodies against Mucin‐1 (MUC1) using engineered glycopeptides on nanoparticle probes. We used a structure‐guided approach to develop unnatural glycopeptides as model antigens for tumor‐associated MUC1. We designed a collection of 13 glycopeptides to bind either SM3 or 5E5, two monoclonal antibodies with distinct epitopes known to recognize tumor associated MUC1. Glycopeptide binding to SM3 or 5E5 was confirmed by surface plasmon resonance and rationalized by molecular dynamics simulations. These model antigens were conjugated to gold nanoparticles and used in a dot‐blot assay to detect autoantibodies in serum samples from pancreatic cancer patients and healthy volunteers. Nanoparticle probes with glycopeptides displaying the SM3 epitope did not have diagnostic potential. Instead, nanoparticle probes displaying glycopeptides with high affinity for 5E5 could discriminate between cancer patients and healthy controls. Remarkably, the best‐discriminating probes show significantly better true and false positive rates than the current clinical biomarkers CA19‐9 and carcinoembryonic antigen (CEA).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Química, Instituto de Investigación en Química (IQUR), Universidad de La Rioja, Logroño, 26006 Logroño, Spain.
- Department of Biotechnology, University of Verona, Strada Le Grazie 15, 37134, Verona, Italy.
- Department of Neurosciences, Biomedicine and Movement Sciences, GM Lab, University of Verona, 37134, Verona, Italy.
- Medical Oncology Department, Hospital San Pedro, Logroño, 26006 Logroño, Spain.
- Oncology Area, Angiogenesis Group, Center for Biomedical Research of La Rioja (CIBIR), Logroño, 26006 Logroño, Spain.
- Wadsworth Center, New York State Department of Health, Biggs Laboratory, Corning Tower, ESP. 12201, Albany, NY, USA.
ORCID-Profile: Francisco Corzana, Ander Eguskiza, Elisa De Tomi, Alfonso Martín-Carnicero, María P Martínez-Moral, Vincenzo Mangini, Francesco Papi, Carmen Bretón, Paula Oroz, Laura Lagartera, Ester Jiménez-Moreno, Alberto Avenoza, Jesús H Busto, Cristina Nativi, Juan L Asensio, Ramón Hurtado-Guerrero, Jesús M Peregrina, Giovanni Malerba, Alfredo Martínez, Roberto Fiammengo
Förderung
- HORIZON EUROPE Marie Sklodowska-Curie Actions
- Mizutani Foundation for Glycoscience
- Fundación Científica Asociación Española Contra el Cáncer
- Agencia Estatal de Investigación
- Universidad de La Rioja
- Departamento de Educación, Cultura y Deporte, Gobierno de Aragón
- Fondazione AIRC per la ricerca sul cancro ETS
Zitieren
APA
Corzana, F., Asín, A., Eguskiza, A., De Tomi, E., Martín-Carnicero, A., Martínez-Moral, M. P., Mangini, V., Papi, F., Bretón, C., Oroz, P., Lagartera, L., Jiménez-Moreno, E., Avenoza, A., Busto, J. H., Nativi, C., Asensio, J. L., Hurtado-Guerrero, R., Peregrina, J. M., Malerba, G., …, & Fiammengo, R. (2024). Detection of Tumor‐Associated Autoantibodies in the Sera of Pancreatic Cancer Patients Using Engineered MUC1 Glycopeptide Nanoparticle Probes. Angewandte Chemie International Edition, 63(37). https://doi.org/10.1002/anie.202407131
Vancouver
Corzana F, Asín A, Eguskiza A, De Tomi E, Martín-Carnicero A, Martínez-Moral MP, et al. Detection of Tumor‐Associated Autoantibodies in the Sera of Pancreatic Cancer Patients Using Engineered MUC1 Glycopeptide Nanoparticle Probes. Angewandte Chemie International Edition. 2024;63(37). doi:10.1002/anie.202407131
BibTeX
@article{Corzana2024,
author = {Corzana, Francisco and Asín, Alicia and Eguskiza, Ander and De Tomi, Elisa and Martín-Carnicero, Alfonso and Martínez-Moral, María P and Mangini, Vincenzo and Papi, Francesco and Bretón, Carmen and Oroz, Paula and Lagartera, Laura and Jiménez-Moreno, Ester and Avenoza, Alberto and Busto, Jesús H and Nativi, Cristina and Asensio, Juan L and Hurtado-Guerrero, Ramón and Peregrina, Jesús M and Malerba, Giovanni and Martínez, Alfredo and Fiammengo, Roberto},
title = {Detection of Tumor‐Associated Autoantibodies in the Sera of Pancreatic Cancer Patients Using Engineered MUC1 Glycopeptide Nanoparticle Probes},
journal = {Angewandte Chemie International Edition},
year = {2024},
volume = {63},
number = {37},
doi = {10.1002/anie.202407131}
}
EUVIMED